Literature DB >> 31618441

Novel genetic variants in KIF16B and NEDD4L in the endosome-related genes are associated with nonsmall cell lung cancer survival.

Sen Yang1,2,3, Dongfang Tang2,3, Yu C Zhao2,3, Hongliang Liu2,3, Sheng Luo4, Thomas E Stinchcombe2,5, Carolyn Glass2,6, Li Su7, Sipeng Shen7, David C Christiani7,8, Qiming Wang1, Qingyi Wei2,3,5.   

Abstract

The endosome is a membrane-bound organ inside most eukaryotic cells, playing an important role in adaptive immunity by delivering endocytosed antigens to both MHC class I and II pathways. Here, by analyzing genotyping data from two published genome-wide association studies (GWASs), we evaluated associations between genetic variants in the endosome-related gene-set and survival of patients with nonsmall cell lung cancer (NSCLC). The discovery included 44,112 (3,478 genotyped and 40,634 imputed) single-nucleotide polymorphisms (SNPs) in 220 genes in a singlelocus analysis for their associations with survival of 1,185 NSCLC patients from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. After validation of the 821 survival-associated significant SNPs in additional 984 NSCLC patients from the Harvard Lung Cancer Susceptibility Study, 14 SNPs remained significant. The final multivariate stepwise Cox proportional hazards regression modeling of the PLCO dataset identified three potentially functional and independent SNPs (i.e., KIF16B rs1555195 C>T, NEDD4L rs11660748 A>G and rs73440898 A>G) with an adjusted hazards ratio (HR) of 0.86 (95% confidence interval [CI] = 0.79-0.94, p = 0.0007), 1.31 (1.16-1.47, p = 6.0 × 10-5 ) and 1.27 (1.12-1.44, p = 0.0001) for overall survival (OS), respectively. Combined analysis of the adverse genotypes of these three SNPs revealed a trend in the genotype-survival association (ptrend < 0.0001 for OS and ptrend < 0.0001 for disease-specific survival). Furthermore, the survival-associated KIF16B rs1555195T allele was significantly associated with decreased mRNA expression levels of KIF16B in both lung tissues and blood cells. Therefore, genetic variants of the endosome-related genes may be biomarker for NSCLC survival, possibly through modulating the expression of corresponding genes.
© 2019 UICC.

Entities:  

Keywords:  endosome pathway; genome-wide association study; nonsmall cell lung cancer; single-nucleotide polymorphism; survival

Mesh:

Substances:

Year:  2019        PMID: 31618441      PMCID: PMC8096203          DOI: 10.1002/ijc.32739

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  49 in total

1.  Late endosomes derive from early endosomes by maturation.

Authors:  W Stoorvogel; G J Strous; H J Geuze; V Oorschot; A L Schwartz
Journal:  Cell       Date:  1991-05-03       Impact factor: 41.582

2.  Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Authors:  William G Hocking; Ping Hu; Martin M Oken; Stephen D Winslow; Paul A Kvale; Philip C Prorok; Lawrence R Ragard; John Commins; David A Lynch; Gerald L Andriole; Saundra S Buys; Mona N Fouad; Carl R Fuhrman; Claudine Isaacs; Lance A Yokochi; Thomas L Riley; Paul F Pinsky; John K Gohagan; Christine D Berg
Journal:  J Natl Cancer Inst       Date:  2010-05-04       Impact factor: 13.506

3.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

4.  Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Authors:  Luis Paz-Ares; Alexander Luft; David Vicente; Ali Tafreshi; Mahmut Gümüş; Julien Mazières; Barbara Hermes; Filiz Çay Şenler; Tibor Csőszi; Andrea Fülöp; Jerónimo Rodríguez-Cid; Jonathan Wilson; Shunichi Sugawara; Terufumi Kato; Ki Hyeong Lee; Ying Cheng; Silvia Novello; Balazs Halmos; Xiaodong Li; Gregory M Lubiniecki; Bilal Piperdi; Dariusz M Kowalski
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

Review 5.  [Single nucleotide polymorphisms in lung cancer patients and cisplatin treatment].

Authors:  Agnieszka Stenzel-Bembenek; Dariusz Sagan; Małgorzata Guz; Andrzej Stepulak
Journal:  Postepy Hig Med Dosw (Online)       Date:  2014-11-25       Impact factor: 0.270

Review 6.  NLRC5: a key regulator of MHC class I-dependent immune responses.

Authors:  Koichi S Kobayashi; Peter J van den Elsen
Journal:  Nat Rev Immunol       Date:  2012-12       Impact factor: 53.106

Review 7.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

8.  Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer.

Authors:  Balázs Győrffy; Pawel Surowiak; Jan Budczies; András Lánczky
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

9.  Comprehensive molecular profiling of lung adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-09       Impact factor: 49.962

10.  HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease.

Authors:  Lucas D Ward; Manolis Kellis
Journal:  Nucleic Acids Res       Date:  2015-12-10       Impact factor: 16.971

View more
  1 in total

1.  Downregulation of NEDD4L by EGFR signaling promotes the development of lung adenocarcinoma.

Authors:  Guoyin Li; Zewen Song; Changjing Wu; XiaoYan Li; Liping Zhao; Binghua Tong; Zhenni Guo; Meiqing Sun; Jin Zhao; Huina Zhang; Lintao Jia; Shengqing Li; Lei Wang
Journal:  J Transl Med       Date:  2022-01-28       Impact factor: 5.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.